Patents by Inventor Hanns Wurziger
Hanns Wurziger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030075557Abstract: When chemical substances are pipetted in individual microwells of a microwell array (4), problematic evaporation effects arise concerning the solvent with which the microwells are already filled. In order to prevent such undesired evaporation effects, a pipetting device for the automated pipetting of chemical substances having a holder (3), which receives at least one microwell array (4), and a pipetting head (11), which is fitted in such a way that it can be moved, is designed with the pipetting head (11) being fastened, by means of a holding device, to a plate (7) which follows the movements of the pipetting head (11) during the pipetting process. The plate (7) forms above the microwell array (4), in conjunction with a frame (5) tightly enclosing the microwell array (4), a sealed gas space (14) into which the pipetting head (11) protrudes through a matched hole (13) in the plate (7).Type: ApplicationFiled: October 28, 2002Publication date: April 24, 2003Inventors: Holger Deppe, Hanns Wurziger, Alexander Gross, Dirk Tomandl, Andreas Schober
-
Publication number: 20030055293Abstract: The present invention relates to a process for the epoxidation of olefins.Type: ApplicationFiled: October 28, 2002Publication date: March 20, 2003Inventors: Hanns Wurziger, Guido Pieper, Norbert Schwesinger
-
Publication number: 20030045747Abstract: The present invention relates to a process for the Baeyer-Villiger oxidation of organic carbonyl compounds.Type: ApplicationFiled: September 12, 2002Publication date: March 6, 2003Inventors: Hanns Wurziger, Guido Pieper, Norbert Schwesinger
-
Patent number: 6492368Abstract: Novel compounds of the formula I in which X, Y, R1, R2 and R3 are as defined in Patent Claim 1 are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.Type: GrantFiled: March 31, 2000Date of Patent: December 10, 2002Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Hanns Wurziger, Guido Melzer, Horst Juraszyk, Sabine Bernotat-Danielowski
-
Patent number: 6492384Abstract: The invention relates to novel compounds of formula (I), wherein R, R1, R2, R3, n and p have the meaning defined in claim 1. Compounds are inhibitors of clotting factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic disorders.Type: GrantFiled: December 13, 2001Date of Patent: December 10, 2002Assignee: Merck Patent GmbHInventors: Werner Mederski, Horst Juraszyk, Hanns Wurziger, Joachim Gante, Dieter Dorsch, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer, Soheila Anzali
-
Patent number: 6488315Abstract: A coupling for microcomponents has several essentially plane-parallel plates with line connections for delivering and discharging liquid or gaseous components. The line connections are mounted on a connection block which protrudes through openings in the plates with fixing segments that engage a pressure plate retained by a clip. The line connections open out in an area of line bores in the plate.Type: GrantFiled: April 27, 2000Date of Patent: December 3, 2002Assignee: Merck Patent GmbHInventors: Günter Brenner, Michael Schmelz, Hanns Wurziger, Norbert Schwesinger
-
Patent number: 6455529Abstract: Compounds of the formula I in which R1, R2 and R3 have the stated meanings, and their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporoses, oncoses, stroke, myocardial infarct, ischemias, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: May 3, 1996Date of Patent: September 24, 2002Assignee: Merck Patent Gesellschaft mit beschraenkter HaftungInventors: Joachim Gante, Hörst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 6380430Abstract: Novel compounds of the formula I in which X, R1, R2, R3, R4 and R5 have the meaning indicated in Patent Claim 1, are inhibitors of the coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.Type: GrantFiled: December 29, 2000Date of Patent: April 30, 2002Assignee: Merck Patent Gesellschaft mit beschraenkterHaftungInventors: Dieter Dorsch, Horst Juraszyk, Werner Mederski, Joachim Gante, Hanns Wurziger, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 6204280Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: September 30, 1998Date of Patent: March 20, 2001Assignee: Merck Patent Gesellschaft mit berschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
-
Patent number: 6153627Abstract: Chroman derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 have the meanings defined herein, and their salts have an effect on the cardiovascular system.Type: GrantFiled: June 6, 1995Date of Patent: November 28, 2000Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Gunther Hausler, Rolf Gericke, Hanns Wurziger, Manfred Baumgarth, Inge Lues, Jacques De Peyer, Rolf Bergmann
-
Patent number: 6040308Abstract: Chroman derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 have the meanings defined herein, and their salts have an effect on the cardiovascular system.Type: GrantFiled: October 28, 1994Date of Patent: March 21, 2000Assignee: Merck Gesellschaft mit beschrankter HaftungInventors: Gunther Hausler, Rolf Gericke, Hanns Wurziger, Manfred Baumgarth, Inge Lues, Jacques De Peyer, Rolf Bergmann
-
Patent number: 6028090Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: November 6, 1997Date of Patent: February 22, 2000Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5776937Abstract: Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: November 7, 1995Date of Patent: July 7, 1998Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5723480Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: May 29, 1996Date of Patent: March 3, 1998Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5627197Abstract: Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: February 14, 1996Date of Patent: May 6, 1997Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5614531Abstract: Compounds of the formula I ##STR1## and the corresponding 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives, their physiologically acceptable salts and/or solvates, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporosis, oncoses, stroke, myocardial infarct, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: February 17, 1995Date of Patent: March 25, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5614535Abstract: Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.Type: GrantFiled: August 18, 1995Date of Patent: March 25, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5561148Abstract: Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,X is O, S, SO, SO.sub.2, --NH-- or --NA--,B is ##STR2## or ##STR3## A is alkyl having from 1 to 6 C atoms,R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl,R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2,E is, in each case independently of each other, CH or N,Q is O, S or NH,m is 1, 2 or 3, andn is 0, 1, 2 or 3,and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.Type: GrantFiled: September 22, 1994Date of Patent: October 1, 1996Assignee: Merck Patent Gesellschaft Mit Beshrankter HaftungInventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Guido Melzer, Sabine Bernotat-Danielowski
-
Patent number: 5532255Abstract: Compounds of the formula ##STR1## in which R.sup.1, X and Y have the meanings defined herein, and their salts, inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and tumors.Type: GrantFiled: April 29, 1994Date of Patent: July 2, 1996Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Peter Raddatz, Joachim Gante, Horst Juraczyk, Hanns Wurziger, Helmut Prucher, Sabine Bernotat-Danielowski, Guido Melzer
-
Patent number: 5387587Abstract: Chroman derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 have the meanings defined herein, and their salts have an effect on the cardiovascular system.Type: GrantFiled: September 27, 1991Date of Patent: February 7, 1995Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Gunther Hausler, Rolf Gericke, Hanns Wurziger, Manfred Baumgarth, Inge Lues, Jacques De Peyer, Rolf Bergmann